Navidea Biopharmaceuticals Inc (NAVB)

[XJINVESTOR]

Dead stock the last couple months waiting on this deal to be done. Stock ran a few months ago to 1.14 Sept. 22nd due to rumors this might be resolved, but that was squelched and it sank back down again.

This deal is HUGE for this company. First off, it takes the millstone of an egregious lender that was more concerned with running the company out of business than it was collecting the debt payment. They will now be officially OUT of the picture and I hope no other company deals with them ever again after seeing this fiasco.

The debt is paid in full - this also saved the company 6.7 million a year just in interest payments.

The company's main drug, Lymphoseek will still be available for European sales. Also a couple other promising drugs are in the pipeline.

80 million upfront - plus 20.1 million for the next 3 years.

Massive short positions could really squeeze here as they did not expect this deal to get done. You could see a lot of covering here and that could push this up very very high.

Get in while you can - this will be on a lot of watchlists and it will fly over 1.50 in the very near term!